Aminkeng Zawuo Leke

Aminkeng Zawuo Leke

Auto-generated profile, based on publicly available information

Aminkeng Zawuo Leke

Centre for Maternal and Infant Research Health Research Foundation (HRF) Buea Cameroon

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in Reproductive Toxicology
Verified
Journal Article
Closed access
ALAminkeng Zawuo Leke
Aminkeng Zawuo Leke
HDHelen Dolk
Helen Dolk
M:Maria :oane
Maria :oane
KCKaren Casson
Karen Casson
VNVera Nelen
Vera Nelen
DTDavid Tucker
David Tucker

20 November 2018 in BMC Pregnancy and Childbirth
Verified
Journal Article
Open access
PDF file
ALAminkeng Zawuo Leke
Aminkeng Zawuo Leke
HDHelen Dolk
Helen Dolk
M:Maria :oane
Maria :oane
KCKaren Casson
Karen Casson
NMNkwati Michel Maboh
Nkwati Michel Maboh
DEDerick Etiendem
Derick Etiendem
There is a paucity of epidemiological data on medication use in pregnancy in Cameroon. Between March and August 2015, 795 pregnant women attending 8 urban and 12 rural hospitals in Cameroon for antenatal (ANC) or other care were interviewed on first trimester medication use using structured questionnaires. Multivariate logistic regression was used to analyse the association of 18 sociodemographic factors with medication use. A total of 582 (73.2%) women took at least one orthodox (Western) medication during the first trimester, 543 (68.3%) women a non-pregnancy related orthodox medication, and 336 (42.3%)women a pregnancy related orthodox medication. 44% of the women took anti-infectives including antimalarials (33.6%) and antibiotics (20.8%).The other most common medications were analgesics (48.8%) and antianaemias (38.6%). Sulfadoxine/pyrimethamine, contraindicated in the first trimester of pregnancy, was the most commonly used antimalarial(13% of women).0.2% of women reported antiretroviral use. Almost 80% of all orthodox medications consumed by women were purchased from the hospital. 12.8% of the women self-prescribed. Health unit and early gestational age at ANC booking were consistent determinants of prescribing of non-pregnancy related, pregnancy related and anti-infective medications. Illness and opinion on the safety of orthodox medications were determinants of the use of non-pregnancy related medications and anti-infectives. Age and parity were associated only with non-pregnancy related medications. This study has confirmed the observations of studies across Africa indicating the increasing use of medications during pregnancy. This is an indication that access to medicine is improving and more emphasis now must be placed on medication safety systems targeting pregnant women, especially during the first trimester when the risk of teratogenicity is highest.

5 May 2021 in Birth Defects Research
Verified
Journal Article
Open access
PDF file
HDHelen Dolk
Helen Dolk
ALAminkeng Zawuo Leke
Aminkeng Zawuo Leke
PWPhil Whitfield
Phil Whitfield
RMRebecca Moore
Rebecca Moore
KKKaty Karnell
Katy Karnell
DVDiana Valencia
Diana Valencia
Background: Surveillance programs in low‐ and middle‐income countries (LMICs) have difficulty in obtaining accurate information about congenital anomalies.Methods: As part of the ZikaPLAN project, an International Committee developed an app for the description and coding of congenital anomalies that are externally visible at birth, for use in low resource settings. The “basic” version of the app was designed for a basic clinical setting and to overcome language and terminology barriers by providing diagrams and photos, sourced mainly from international Birth Defects Atlases. The “surveillance” version additionally allows recording of limited pseudonymized data relevant to diagnosis, which can be uploaded to a secure server, and downloaded by the surveillance program data center.Results: The app contains 98 (88 major and 10 minor) externally visible anomalies and 12 syndromes (including congenital Zika syndrome), with definitions and International Classification of Disease v10 ‐based code. It also contains newborn examination videos and links to further resources. The user taps a region of the body, then selects among a range of images to choose the congenital anomaly that best resembles what they observe, with guidance regarding similar congenital anomalies. The “basic” version of the app has been reviewed by experts and made available on the Apple and Google Play stores. Since its launch in November 2019, it has been downloaded in 39 countries. The “surveillance” version is currently being field‐tested.Conclusion: The global birth defects app is a mHealth tool that can help in developing congenital anomaly surveillance in low resource settings to support prevention and care.

28 June 2023 in PLOS Global Public Health
Verified
Journal Article
Open access
PDF file
ALAminkeng Zawuo Leke
Aminkeng Zawuo Leke
HMHelen Malherbe
Helen Malherbe
EKEmma Kalk
Emma Kalk
UMUshma Mehta
Ushma Mehta
PKPhylis Kisa
Phylis Kisa
LBLinda Barlow-Mosha
Linda Barlow-Mosha
The aim of this scoping review was to determine the scope, objectives and methodology of contemporary published research on congenital anomalies (CAs) in sub-Saharan Africa (SSA), to inform activities of the newly established sub-Saharan African Congenital Anomaly Network (sSCAN). MEDLINE was searched for CA-related articles published between January 2016 and June 2021. Articles were classified into four main areas (public health burden, surveillance, prevention, care) and their objectives and methodologies summarized. Of the 532 articles identified, 255 were included. The articles originated from 22 of the 49 SSA countries, with four countries contributing 60% of the articles: Nigeria (22.0%), Ethiopia (14.1%), Uganda (11.7%) and South Africa (11.7%). Only 5.5% of studies involved multiple countries within the region. Most articles included CA as their primary focus (85%), investigated a single CA (88%), focused on CA burden (56.9%) and care (54.1%), with less coverage of surveillance (3.5%) and prevention (13.3%). The most common study designs were case studies/case series (26.6%), followed by cross-sectional surveys (17.6%), retrospective record reviews (17.3%), and cohort studies (17.2%). Studies were mainly derived from single hospitals (60.4%), with only 9% being population-based studies. Most data were obtained from retrospective review of clinical records (56.1%) or via caregiver interviews (34.9%). Few papers included stillbirths (7.5%), prenatally diagnosed CAs (3.5%) or terminations of pregnancy for CA (2.4%).This first-of-a-kind-scoping review on CA in SSA demonstrated an increasing level of awareness and recognition among researchers in SSA of the contribution of CAs to under-5 mortality and morbidity in the region. The review also highlighted the need to address diagnosis, prevention, surveillance and care to meet Sustainable Development Goals 3.2 and 3.8. The SSA sub-region faces unique challenges, including fragmentation of efforts that we hope to surmount through sSCAN via a multidisciplinary and multi-stakeholder approach.

30 August 2022 in PLOS Global Public Health
Verified
Journal Article
Open access
PDF file
ALAminkeng Zawuo Leke
Aminkeng Zawuo Leke
HDHelen Dolk
Helen Dolk
M:Maria :oane
Maria :oane
KCKaren Casson
Karen Casson
NMNkwati Michel Maboh
Nkwati Michel Maboh
DEDerick Etiendem
Derick Etiendem
To examine the prevalence, determinants and attitude towards herbal medication (HM) use in the first trimester of pregnancy in Cameroon women. Between March to August 2015, we surveyed 795 pregnant women attending 20 randomly selected urban or rural hospitals in South West Cameroon on first trimester orthodox medication (OM) and HM use. Data was obtained by interviews using structured questionnaires. First trimester HM use was reported by 293 (36∙9%) women, 76% of whom used it in combination with OM. The most frequent indication for taking HM was prevention/treatment of anaemia (26∙3%). The HM were usually self-prescribed (33∙3%) or by family (56∙2%), and obtained from the woman’s own garden (69∙3%). Twenty percent of women believed that HM was always safe to take in pregnancy, compared to 69.3% for OM. Intake of HM was significantly influenced by women’s opinion on OM or HM safety—the odds of taking HM was 3 time higher among women who were unsure about the safety of OM (AOR: 3∙0, 95%CI = 1∙5–6∙1), while women who thought HM were never safe or who were unsure about its safety, were 91% or 84% respectively less likely to take HM compared to women who believed HM were always safe. We identified a high prevalence of HM use and concomitant use with OM, strongly influenced by women’s perception of HM and OM safety. These findings indicate the need for WHO to specifically address safety in pregnancy in its policy to integrate traditional medicine use into existing healthcare systems in Africa.

30 October 2025 in JMIR Research Protocols
Verified
Journal Article
Open access
ALAminkeng Zawuo Leke
Aminkeng Zawuo Leke
LDLionel Landry Sop Deffo
Lionel Landry Sop Deffo
YWYunkavi Sabastian Wirsiy
Yunkavi Sabastian Wirsiy
TAThomas James Aldersley
Thomas James Aldersley
TDThomas Day
Thomas Day
HDHelen Dolk
Helen Dolk
Background: Sub-Saharan Africa (SSA) bears the highest global burden of under-5 mortality, with congenital heart disease (CHD) as a major contributor. Despite advancements in high-income countries, CHD-related mortality in SSA remains largely unchanged due to limited diagnostic capacity and centralized health care. While pulse oximetry aids early detection, confirmation typically relies on echocardiography, a procedure constrained by a shortage of specialized personnel. Artificial intelligence (AI) offers a promising solution to bridge this diagnostic gap. Objective: This study aims to develop an AI-assisted echocardiography system that enables nonexpert operators, such as nurses, midwives, and medical doctors, to perform basic cardiac ultrasound sweeps on neonates suspected of CHD and extract accurate cardiac images for remote interpretation by a pediatric cardiologist. Methods: The study will use a 2-phase approach to develop a deep learning model for real-time cardiac view detection in neonatal echocardiography, utilizing data from St. Padre Pio Hospital in Cameroon and the Red Cross War Memorial Children’s Hospital in South Africa to ensure demographic diversity. In phase 1, the model will be pretrained on retrospective data from nearly 500 neonates (0-28 days old). Phase 2 will fine-tune the model using prospective data from 1000 neonates, which include background elements absent in the retrospective dataset, enabling adaptation to local clinical environments. The datasets will consist of short and continuous echocardiographic video clips covering 10 standard cardiac views, as defined by the American Society of Echocardiography. The model architecture will leverage convolutional neural networks and convolutional long short-term memory layers, inspired by the interleaved visual memory framework, which integrates fast and slow feature extractors via a shared temporal memory mechanism. Video preprocessing, annotation with predefined cardiac view codes using Labelbox, and training with TensorFlow and PyTorch will be performed. Reinforcement learning will guide the dynamic use of feature extractors during training. Iterative refinement, informed by clinical input, will ensure that the model effectively distinguishes correct from incorrect views in real time, enhancing its usability in resource-limited settings. Results: Retrospective data collection for the project began in September 2024, and to date, data from 308 babies have been collected and labeled. In parallel, the initial model framework has been developed and training initiated using a subset of the labeled data. The project is currently in the intensive execution phase, with all objectives progressing in parallel and final results expected within 10 months. Conclusions: The AI-assisted echocardiography model developed in this project holds promise for improving early CHD diagnosis and care in SSA and other low-resource settings. International Registered Report Identifier (IRRID): DERR1-10.2196/75270